Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Investments (2017 - 2025)

Corcept Therapeutics' Long-Term Investments history spans 9 years, with the latest figure at $160.3 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 27.09% year-over-year to $160.3 million; the TTM value through Dec 2025 reached $160.3 million, down 27.09%, while the annual FY2025 figure was $160.3 million, 27.09% down from the prior year.
  • Long-Term Investments for Q4 2025 was $160.3 million at Corcept Therapeutics, up from $102.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $248.0 million in Q1 2025 and bottomed at $4.9 million in Q3 2022.
  • The 5-year median for Long-Term Investments is $91.7 million (2021), against an average of $95.6 million.
  • The largest annual shift saw Long-Term Investments soared 2320.4% in 2021 before it plummeted 96.34% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $112.3 million in 2021, then crashed by 95.59% to $4.9 million in 2022, then skyrocketed by 1055.77% to $57.2 million in 2023, then soared by 284.48% to $219.8 million in 2024, then dropped by 27.09% to $160.3 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Long-Term Investments are $160.3 million (Q4 2025), $102.6 million (Q3 2025), and $172.8 million (Q2 2025).